The GLP-1 Coverage Debate: What Employers Are Missing

The GLP-1 Coverage Debate: What Employers Are Missing

Six months ago, Cigna quietly told its own employees that it would stop paying for GLP-1 drugs used for weight loss, a move Forbes covered as part of a broader pullback among health plans confronting the cost of these drugs at scale. Blue Cross Blue Shield of Massachusetts and Point32Health had already done something similar earlier in the year, according to a Boston Globe column on the state's benefits landscape. Meanwhile, a competing set of numbers tells the opposite story. A survey covered by BenefitsPro found that 93% of employees without coverage say they would start a GLP-1 if their employer reimbursed it, and a separate NFP report cited by CNBC found that 29% of employees would switch jobs to gain access to the benefit. The result is a striking disconnect. Some employers and health plans are scaling back coverage, while many employees say access to GLP-1 medications would influence both their treatment decisions and even where they choose to work.

That contradiction is the real story here, and it explains why "should employers cover GLP-1s" has become the single most argued-about question in benefits strategy right now. It is being debated in boardrooms, in broker renewal meetings, and in HR Slack channels every single week. The honest answer is not yes or no. It is that the question itself is incomplete. The coverage decision was never really about whether GLP-1s work. It is about whether an employer has built the infrastructure to make them work at scale, for a whole population, without the cost spiraling out of control. Most have not. That gap, more than the price of the drug itself, is what is quietly deciding this debate.

‍

The Cost Argument Isn't Wrong, It's Incomplete.

Anyone who has sat through a pharmacy benefits renewal meeting in the last two years knows the numbers by heart. GLP-1s can run well into the thousands of dollars a year per person before rebates. A case study from insurance brokerage AssuredPartners, detailed by HRP, found that GLP-1 use lowered medical costs by roughly $560 per user annually, a fraction of the roughly $6,540 the drugs cost on average in that same analysis. On paper, the math looks brutal, and it is part of the reason 51% of employers in an NFP survey reported by CNBC now name GLP-1s as the single biggest driver of rising drug spend.

There is a second, quieter problem sitting underneath the price tag: most people who start a GLP-1 do not stay on it. Data cited by Personify Health shows that Blue Health Intelligence found 30% of patients stop within the first 30 days, and Evernorth research puts the one-year dropout rate near 50%. A Prime Therapeutics analysis, referenced by Managed Healthcare Executive, found that only about 8% of participants were still on therapy after three years. Every one of those early exits represents a plan that paid full freight for a treatment that never got the chance to deliver a return.

The skepticism is understandable. When GLP-1s are evaluated as a pharmacy expense alone, the financial return can be difficult to demonstrate in the short term. Medication costs are immediate, while many of the potential clinical and financial benefits accrue over time.

That distinction is important because medication coverage and population health management are not the same thing. Covering a prescription gives eligible employees access to treatment. Achieving meaningful health outcomes often depends on what happens after treatment begins, including clinical oversight, ongoing engagement, adherence support, and regular evaluation of progress. As employers continue to assess GLP-1 strategies, the question is increasingly shifting from whether to cover these medications to how they are delivered and supported over time.

‍

‍

The Evidence Beyond the Headlines

Look past the discontinuation headlines and a more encouraging picture emerges. Aon analyzed claims from 192,000 GLP-1 users across a population of more than 50 million people. As summarized by Managed Healthcare Executive, participants who remained on therapy for at least 18 months with program adherence above 80% experienced slower medical cost growth and fewer hospitalizations for major cardiovascular events. The findings suggest that long-term outcomes depend not only on access to medication, but also on keeping patients engaged in treatment.

Employer demand for GLP-1 access remains significant. A Business Group on Health survey, reported by Pharmaceutical Commerce, found that 67% of surveyed employers currently cover GLP-1s for weight management. At the same time, obesity-related illness continues to carry substantial costs. The Centers for Disease Control and Prevention reports that obesity accounted for $173 billion in direct annual medical costs in 2019, while the Peterson Health Technology Institute reports that obesity-related conditions resulted in $243 billion in lost workplace productivity in 2023.

Taken together, these findings shift the conversation. The question is no longer whether GLP-1s work clinically. It is whether employers have the clinical infrastructure to help participants stay on therapy long enough to realize those benefits.

The Missing Piece

GLP-1 medications have demonstrated meaningful clinical benefits for many patients, but access to a prescription is only one part of long-term treatment. Maintaining engagement over months or years often requires ongoing clinical oversight, regular follow-up, support for managing side effects, and periodic evaluation to determine whether treatment continues to provide meaningful clinical benefit. For employers, the design of the care model can be just as important as the coverage decision itself.

A real-world survey of physicians and patients, published on PMC, reveals a communication gap that explains a lot of the dropout data. When researchers asked why patients discontinue GLP-1 therapy, doctors most often blamed inadequate blood sugar control. Patients overwhelmingly said something different: they felt sick, or they threw up, and nobody helped them manage it in time. That gap between what a clinician assumes is happening and what a patient is experiencing is where adherence quietly dies. It does not die because the drug failed. It dies because nobody was watching closely enough to intervene before the person gave up.

This is the part of the conversation that often gets overlooked. Coverage decisions are frequently treated as a binary choice, when the research suggests the care model surrounding the prescription also plays an important role. Elements such as ongoing biomarker monitoring, timely clinician access, regular follow-up, and individualized treatment adjustments may help address many of the barriers to long-term adherence identified in the literature. Employers evaluating GLP-1 programs should consider not only whether the medication is covered, but also how participants are supported after treatment begins. One example is eMed's Population Health GLP-1 Program for Employers, which was designed around many of these principles.

‍

What a Program Built to Work Looks Like

eMed's Population Health GLP-1 Program for Employers is designed to address this gap. Rather than treating a GLP-1 prescription as the end of care, eMed approaches obesity as a population health challenge by combining medication, when clinically appropriate, with at-home biomarker screening, clinician oversight, ongoing adherence support, and preventive care services. The goal is to identify risk earlier, keep participants engaged throughout treatment, and support the long-term management of obesity and related chronic conditions.

The financial model is evolving as well. Through its partnership with CVS Caremark, reported by Axios, employers can determine how the Fixed Fee Program is structured, independent of traditional health plan coverage.

Early results have been encouraging. eMed's internal program data indicate participants have achieved medication adherence above 90% and average participant weight loss of approximately 21 pounds.

Taken together, the approach reflects a broader shift in how some employers are evaluating GLP-1 programs. Rather than focusing exclusively on pharmacy coverage, the conversation is expanding to include clinical oversight, participant engagement, measurable outcomes, and benefit designs that give employers greater flexibility in how they support access to treatment.

‍

‍

‍

The Question Employers Should Be Asking

Instead of asking whether to cover GLP-1s, employers should ask whether they have, or can access, the clinical infrastructure needed to support meaningful long-term outcomes. Coverage is only one part of the equation. Without the right clinical support, even a generous benefit may struggle to deliver lasting value.

GLP-1 therapies are likely to remain an important part of employer-sponsored healthcare. Employee demand continues to grow, and new therapies will likely expand treatment options over time. The employers best positioned for success may not be those that simply chose to cover GLP-1s, but those that recognized early that coverage and program design are inseparable.

‍

_{Disclaimer: This blog is maintained by eMed for informational purposes only. Content published here does not constitute medical, legal, financial, or benefits advice and should not be relied upon as such. Third-party statistics, studies, and research cited are sourced from publicly available data and provided for general informational context only; eMed makes no representation as to their accuracy, completeness, or applicability to any specific employer population, and results may vary. eMed's Population Health GLP-1 Program for Employers pairs FDA-approved, on-label medications with clinical oversight; individual health outcomes depend on a variety of clinical and personal factors and cannot be guaranteed.}

_{Any content authored or posted by eMed employees reflects their personal opinions and perspectives only and does not represent the views, positions, or official statements of eMed or its affiliates}

_‍

_‍